Optimi Health Expands Psilocybin, MDMA Therapy in Australia Under New TGA Framework
OPTH•Optimi Health received final recommendations from Australia's Therapeutic Goods Administration expanding its Authorized Prescriber scheme for GMP-compliant MDMA and psilocybin therapies beyond hospitals to broader care teams. The update accelerates psychedelic-assisted PTSD and treatment-resistant depression offerings by increasing workforce capacity in rural areas and boosting reimbursement options.
1. Australian TGA Framework Revision
Optimi Health secured final recommendations from the Therapeutic Goods Administration to broaden its Authorized Prescriber scheme for psilocybin and MDMA. The revisions allow psychiatrists to prescribe GMP-compliant MDMA for PTSD and psilocybin for treatment-resistant depression in non-hospital settings with expanded therapy teams.
2. Expanded Market Access and Reimbursement
The framework update is poised to accelerate adoption of psychedelic-assisted therapies by increasing certified provider capacity, especially in rural and regional areas. It also opens new reimbursement pathways with both public and private payers, potentially boosting commercial revenues.
3. Safety Record Supports Growth
Since December 2025, no serious adverse events have been reported under Australia’s regulated commercial psychedelic treatment program. This safety record underpins confidence in the world’s most advanced commercial market for prescribed psilocybin and MDMA therapies.
